These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27685028)

  • 1. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
    O'Loughlin E; Hourihan S; Chataway J; Playford ED; Riazi A
    Disabil Rehabil; 2017 Sep; 39(18):1821-1828. PubMed ID: 27685028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
    Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
    Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
    Duddy M; Wilkinson C; Medhurst S; Rhys K
    Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
    Katz Sand I; Krieger S; Farrell C; Miller AE
    Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.
    Giovannetti AM; Pietrolongo E; Borreani C; Giordano A; Schiffmann I; Barabasch A; Heesen C; Solari A;
    PLoS One; 2020; 15(2):e0228587. PubMed ID: 32053608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hopelessness ratings in relapsing-remitting and secondary progressive multiple sclerosis.
    Patten SB; Metz LM
    Int J Psychiatry Med; 2002; 32(2):155-65. PubMed ID: 12269596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
    Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study.
    Bogosian A; Morgan M; Moss-Morris R
    BMJ Open; 2019 Mar; 9(3):e026421. PubMed ID: 30852548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
    Chataway J; Murphy N; Khurana V; Schofield H; Findlay J; Adlard N
    Curr Med Res Opin; 2021 Jun; 37(6):995-1004. PubMed ID: 33733976
    [No Abstract]   [Full Text] [Related]  

  • 12. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-assessment of people with relapsing-remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization-Results of a large-scale cross-sectional online survey (MS Perspectives).
    Bayas A; Schuh K; Christ M
    Mult Scler Relat Disord; 2022 Dec; 68():104166. PubMed ID: 36115289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Executive function is an important consideration for coping strategy use in people with multiple sclerosis.
    Grech LB; Kiropoulos LA; Kirby KM; Butler E; Paine M; Hester R
    J Clin Exp Neuropsychol; 2017 Oct; 39(8):817-831. PubMed ID: 28092209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
    Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis.
    Davies F; Edwards A; Brain K; Edwards M; Jones R; Wallbank R; Robertson NP; Wood F
    BMJ Open; 2015 Jul; 5(7):e007674. PubMed ID: 26201723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH
    Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.